India Pharma Outlook Team | Tuesday, 26 April 2022
Swiss biopharma giant Ferring Pharmaceuticals on Monday opened its integrated R&D and manufacturing facility in Hyderabad’s Genome Valley. The facility, which will develop and commercialise new pharma products, has been set up at an investment of Euro 30 million with an initial job creation of 110 people.
The product development and manufacturing facilities will be housed in two spearate buildings spread over 7,500 sq mt and while about 100 people have be hired already the new hires are expected later, Francois Hosotte, vice president, strategic projects & engineering, Ferring Pharma, said during the inaugural ceremony.
The $2 billion turnover Saint-Prex headquartered Ferring, which operates in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology, will be using the Hyderabad facility for developing and manufacturing urology products based on its proprietary FDG (fast dissolving granules) technology platform followed by gastroenterology related
products.
Telangana industries minister KT Rama Rao said that the new facility, which has unique capabilities in formulations development, packaging development and analytical development, was initally being planned in Maharashtra but Ferring eventually zeroed in on Hyderabad, which was a testament to the overall ecosystem of lifesciences in Telangana and the pro-business policies of the Telangana government.
Pointing out that the Telangana government is working to boost the state’s lifesciences ecosystem from $50 billion to $100 billion by 2030, KTR said: “Hyderabad is that place where biology meets technology, lifesciences meets data science because the points of intersection of information technology and biotechnology is what makes for the exciting opportunties that lie in innovation and disruption.”
“And that is where I think Hyderabad offers a great value propostion for both innovators in India and abroad with its rich network of over 50 strong scientific institutions and a solid thinkforce that offer a lot of opportunities to create IP and solutions for the rest of the world,” he added. With its new Hyderabad facility, the privately-owned biopharma player, which was set up in 1950, now has 14 manufacturing sites and 13 R&D centres globally. It employs about 6,500 people in over 50 countries and markets its products in 110 countries.
, CDSCO.jpg)
